CorMedix IncNASDAQ:CRMD
- LAST PRICE5.2300
- TODAY'S CHANGE (%)-0.0700 (-1.3208%)
- Bid / Lots5.2200/ 2
- Ask / Lots5.2400/ 13
- Open / Previous Close5.2800 / 5.3000
- Day Range
- 52 Week Range
- Volume76,048
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CRMD |
|---|---|---|
| 09:32 ET | 20696 | 5.28 |
| 09:34 ET | 2200 | 5.3 |
| 09:36 ET | 3632 | 5.2 |
| 09:38 ET | 5124 | 5.2885 |
| 09:39 ET | 4284 | 5.24 |
| 09:41 ET | 10385 | 5.22 |
| 09:43 ET | 300 | 5.22 |
| 09:45 ET | 1900 | 5.22 |
| 09:48 ET | 10805 | 5.215 |
| 09:50 ET | 3788 | 5.22 |
| 09:52 ET | 100 | 5.2202 |
| 09:54 ET | 600 | 5.235 |
| 09:56 ET | 2557 | 5.24 |
| 10:01 ET | 703 | 5.22 |
| 10:06 ET | 1600 | 5.23 |
Yesterday
DJ CorMedix Price Target Maintained With a $10.00/Share by Needham, from 5:42AM ET on Monday May 13, 2024 by Dow Jones
5:42AM ET on Monday May 13, 2024 by Dow Jones
May 10, 2024
CorMedix Inc. to Participate in Two Upcoming Investor Conferences, from 8:30AM ET on Friday May 10, 2024 by Dow Jones
8:30AM ET on Friday May 10, 2024 by Dow Jones
May 9, 2024
CorMedix Inc. Reports First Quarter 2024 Financial Results and Provides Business Update, from 7:30AM ET on Thursday May 09, 2024 by Dow Jones
7:30AM ET on Thursday May 09, 2024 by Dow Jones*DJ CorMedix 1Q Loss/Shr 25c >CRMD, from 7:30AM ET on Thursday May 09, 2024 by Dow Jones
7:30AM ET on Thursday May 09, 2024 by Dow Jones
May 6, 2024
CorMedix Inc. To Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 9, 2024, from 8:30AM ET on Monday May 06, 2024 by Dow Jones
8:30AM ET on Monday May 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
CorMedix Inc | 291.4M | -5.6x | --- |
Cipla Ltd | 13.7B | 0.0x | --- |
Zevra Therapeutics Inc | 204.6M | -3.7x | --- |
Dbv Technologies SA | 125.2M | -1.6x | --- |
Assembly Biosciences Inc | 73.8M | -1.2x | --- |
Incannex Healthcare Inc | 41.6M | -7.1x | --- |
Company Information
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
Contact Information
- Headquarters
- 300 Connell Drive, Suite 4200BERKELEY HEIGHTS, NJ, United States 07922
- Phone
- 908-517-9500
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Myron Kaplan
- Director
- Joseph Todisco
- Chief Financial Officer, Executive Vice President
- Matthew David
- Executive Vice President, Head of Clinical and Medical Affairs
- Elizabeth Massonhurlburt
- Executive Vice President, Chief Commercial Officer
- Erin Mistry
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $291.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 55.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.74 |
EPS | $-0.93 |
Book Value | $1.28 |
P/E Ratio | -5.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
